ALK qPCR assay
Device72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
NCT Number: NCT02010047
The anaplastic lymphoma kinase gene(ALK) is mutated approximately 5% of non-small cell lung cancers. Testing for this gene is important because there are drugs known as ALK inhibitors that have been shown to significantly delay the progression of ALK-mutated lung cancers. There are a number of ways to test for the presence of the ALK gene in lung cancer biopsy tissue. One method involves making slides and staining them to detect the ALK protein. This is called immunohistochemistry. Another method called fluorescence in situ hybridization(FISH)is used to detect rearrangements of the ALK gene associated with lung cancer. Although both these tests are widely used to test for ALK gene abnormalities, the techniques may not always find the ALK gene mutation because they are not sensitive enough or not enough cancer cells are present in the lung biopsy.
This study is being performed to determine if a technique called quantitation polymerase chain reaction (qPCR) is as accurate or better at finding the ALK gene mutation in lung cancer biopsy tissue.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Not applicable
BC Cancer Agency-Abbotsford Centre, Abbotsford British Columbia, British Columbia, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
Time frame: Up to 24 weeks after the completing of enrollment of 72 ALK negative and 72 ALK positive tumor blocks
Time frame: After completion of enrollemnt of 72 ALK postive tumor blocks.
British Columbia Cancer Agency
Other
A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.
Acronym: PCRTALK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03088540
Bronchial Neoplasms, Carcinoma, Bronchogenic
Albury, New South Wales, Australia
View Trial DetailsNCT05873439
Bronchial Neoplasms, Carcinoma, Bronchogenic
Tampa, Florida, United States
View Trial DetailsNCT02973789
Bronchial Neoplasms, Carcinoma, Bronchogenic
Birmingham, Alabama, United States
View Trial DetailsNCT05082610
Advanced Solid Tumor, Breast Diseases
Duarte, California, United States
View Trial Details